On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
FDA Advisory Panels: No Means No, Yes Means Maybe
February 6, 2011 By 4 Comments
As the only company to receive a positive United States Food and Drug Administration [FDA] Advisory Committee [AdCom] recommendation for a product candidate to treat obesity in 2010, Orexigen Therapeutics, Inc. (OREX) appeared well positioned to receive marketing approval for Contrave® [naltrexone HCl/bupropion HCI]. However, on January 31, 2011, Orexigen and its partner Takeda Pharmaceutical [...]
Biotech Deal Activity a Mixed Bag During Major Conference
January 17, 2011 By Leave a Comment
Last week, thousands of registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference [JPMHC] to hear 25-minute presentations from 364 life science companies. For industry executives and investors, deal activity emanating from the annual event typically serves as a good barometer for the rest of the year. Adding to an already hectic [...]
2010 Cancer Immunotherapy: A Long-Awaited Reality
October 28, 2010 By Leave a Comment
Selected photos from Cancer Immunotherapy: A Long-Awaited Reality conference hosted by MD Becker Partners and BioBusiness.TV held at the New York Academy of Medicine on October 21, 2010 (Note: Click on photo to enlarge). Alternatively, click here to view a video montage of the conference photos.
Follow MD Becker Partners